Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Node Positive ◽

Randomised Controlled ◽

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

Yearbook of Oncology ◽

10.1016/s1040-1741(10)79516-6 ◽

2010 ◽

Vol 2010 ◽

pp. 19-21

Author(s):

J.T. Thigpen

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Node Positive ◽

Randomised Controlled ◽

Faculty Opinions recommendation of 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718043513.793482079 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Controlled Trial ◽

Her2 Positive ◽

Open Label ◽

Adjuvant Trastuzumab ◽

Her2 Positive Breast Cancer ◽

Randomised Controlled ◽

Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30088-8 ◽

2017 ◽

Vol 18 (3) ◽

pp. 371-383 ◽

Cited By ~ 21

Author(s):

Pin Zhang ◽

Tao Sun ◽

Qingyuan Zhang ◽

Zhongyu Yuan ◽

Zefei Jiang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Controlled Trial ◽

Metastatic Breast ◽

Open Label ◽

Phase 3 ◽

Heavily Pretreated ◽

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial

Annals of Oncology ◽

10.1093/annonc/mdw055 ◽

2016 ◽

Vol 27 (5) ◽

pp. 806-812 ◽

Cited By ~ 8

Author(s):

N. Zdenkowski ◽

J.F. Forbes ◽

F.M. Boyle ◽

G. Kannourakis ◽

P.G. Gill ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Controlled Trial ◽

Adjuvant Endocrine Therapy ◽

Open Label ◽

Hormone Receptor Positive ◽

Randomised Controlled ◽

Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial

European Urology ◽

10.1016/j.eururo.2020.04.021 ◽

2020 ◽

Vol 78 (4) ◽

pp. 630-631

Author(s):

Teele Kuusk ◽

Axel Bex

Keyword(s):

Adjuvant Chemotherapy ◽

Urothelial Carcinoma ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Upper Tract ◽

Re: Alison Birtle, Mark Johnson, John Chester, et al. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. Lancet 2020;395:1268–77

European Urology ◽

10.1016/j.eururo.2020.09.013 ◽

2021 ◽

Vol 79 (1) ◽

pp. e28

Author(s):

Nirmish Singla ◽

Vitaly Margulis

Keyword(s):

Adjuvant Chemotherapy ◽

Urothelial Carcinoma ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Upper Tract ◽

Mark Johnson ◽

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(07)60028-2 ◽

2007 ◽

Vol 369 (9555) ◽

pp. 29-36 ◽

Cited By ~ 1033

Author(s):

Ian Smith ◽

Marion Procter ◽

Richard D Gelber ◽

Sébastien Guillaume ◽

Andrea Feyereislova ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Controlled Trial ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Randomised Controlled ◽

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30404-7 ◽

2017 ◽

Vol 18 (7) ◽

pp. 929-945 ◽

Cited By ~ 29

Author(s):

David Cameron ◽

James P Morden ◽

Peter Canney ◽

Galina Velikova ◽

Robert Coleman ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Multicentre Phase ◽

Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(20)30415-3 ◽

2020 ◽

Vol 395 (10232) ◽

pp. 1268-1277 ◽

Cited By ~ 46

Author(s):

Alison Birtle ◽

Mark Johnson ◽

John Chester ◽

Robert Jones ◽

David Dolling ◽

...

Keyword(s):

Adjuvant Chemotherapy ◽

Urothelial Carcinoma ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Upper Tract ◽

Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial

European Urology ◽

10.1016/j.eururo.2020.04.006 ◽

2020 ◽

Vol 78 (2) ◽

pp. 289-290

Author(s):

Luca Afferi ◽

Marco Moschini ◽

Agostino Mattei ◽

Francesco Montorsi ◽

Alberto Briganti ◽

...

Keyword(s):

Adjuvant Chemotherapy ◽

Urothelial Carcinoma ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Upper Tract ◽